Anteunis L J, Wanders S L, Hendriks J J, Langendijk J A, Manni J J, de Jong J M
Department of Otorhinolaryngology, Academical Hospital, University of Limburg, Maastricht, The Netherlands.
Am J Surg. 1994 Nov;168(5):408-11. doi: 10.1016/s0002-9610(05)80086-8.
Recent clinical reports indicate that patients receiving radiotherapy that includes the auditory system in the treatment volume are likely to develop an irradiation-induced hearing loss. Although the early, presumed reversible, conductive hearing impairment due to secretory otitis media following radiotherapy is a sequela well known by radiation oncologists, permanent hearing loss, both conductive and sensorineural, is believed to be rare. A prospective study was performed enrolling patients receiving postoperative radiotherapy for unilateral parotid tumors. Audiometric results prior to irradiation were compared with those obtained 2 years later. Up to 50% of the patients (9 of 18) developed a clinically relevant hearing loss in the irradiated ear, both conductive and/or sensorineural. The contralateral ear remained unaltered. The hearing loss was permanent in 6 patients (33%) and affected their quality of life. The data suggest that changes occur in the inner ear as well as in the auditory nerve and auditory brain stem with conventional irradiation schemes with daily fractions of 2 to 2.5 Gy with a total dose of 50 Gy.
近期临床报告表明,接受放射治疗且治疗区域包括听觉系统的患者很可能会出现放疗诱发的听力损失。尽管放疗后因分泌性中耳炎导致的早期、推测为可逆的传导性听力障碍是放射肿瘤学家熟知的后遗症,但永久性听力损失,包括传导性和感音神经性听力损失,被认为较为罕见。一项前瞻性研究纳入了接受单侧腮腺肿瘤术后放疗的患者。将放疗前的听力测定结果与两年后获得的结果进行比较。高达50%的患者(18例中的9例)在受照射耳出现了具有临床意义的听力损失,包括传导性和/或感音神经性听力损失。对侧耳未发生变化。6例患者(33%)的听力损失是永久性的,且影响了他们的生活质量。数据表明,采用每日分次剂量为2至2.5 Gy、总剂量为50 Gy的传统放疗方案时,内耳以及听神经和听觉脑干都会发生变化。